Global Cardiac Biomarkers Market to Reach US$3.39 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Cardiac Biomarkers market. The global market for Cardiac Biomarkers is forecast to reach US$3.39 billion by the year 2017. The market for Cardiac Biomarkers is driven by their precision in early detection of risks associated with cardiac diseases that constitute a leading cause of mortality in several developed nations. A major factor driving growth in the global cardiovascular biomarker market is the ability of these biomarkers to make accurate prediction of heart failure in stable patients.

Cardiac Biomarkers: A Global Strategic Business Report

Follow us on LinkedIn - Cardiovascular Disease (CVD) continues to be the leading cause of mortality worldwide, accounting for a whopping 17 million deaths annually. An estimated 30 million people worldwide get afflicted with one or the other form of cardiovascular diseases every year. Heart failure results in the death of over 5 million people every year. Heart Diseases constitute one of the 10 leading causes of death in the lower, middle and high income groups across the globe. Biomarkers provide tremendous support in effective clinical decision making, which is mainly dependent on diagnosing the health status of a patient. Owing to their precision in the early detection of risks associated with cardiac diseases, biomarkers emerged as an invaluable tool in detecting cardiovascular diseases that constitute a leading cause of mortality in several developed nations, including the US. Increasing technological advancements in the area of biomarkers have enabled their use in unconventional applications.

Cardiac biomarkers, used in the diagnosis and prognosis of myocardial infarction and heart failure, are one of the fastest growing segments of the clinical immunoassay diagnostics market. Cardiovascular biomarkers have taken cardiovascular and metabolic disease diagnosis and management to a new level, by enhancing the efficiency of these processes. Inflammatory and lipid biomarkers have been validated as indicators for assessing potential risks of cardiovascular diseases in patients. Their use has been proven to be effective in establishing the cardiovascular disease onset, thus enabling the prevention of conditions, such as coronary thrombosis and stroke. Besides, these biomarkers are capable of accurately assessing risks of Acute Coronary Syndrome (ACS), stroke and other cardiovascular events in the home as well as primary care settings.

The cardiac biomarkers currently available in the market cater to the needs of physicians for the prognosis, diagnosis, and risk assessment of cardiovascular diseases, such as heart failure and myocardial infarction. Researchers are looking out for additional markers that can help in detecting earlier events in the myocardial infarction disease progression, such as markers for plaque instability and myocardial ischemia.

The US represents the single largest market for Cardiac Biomarkers, as stated by the new market research report on Cardiac Biomarkers. Rest of World is likely to emerge as the fastest growing market for Cardiac Biomarkers with a compounded annual growth rate (CAGR) of 11.6% over the analysis period. Cardiac Troponin assay market constitutes the largest cardiac biomarkers test segment. BNP and NT-pro BNP assay test market is likely to emerge as the fastest growing segment reflecting a compounded annual growth rate (CAGR) of 15.6% over the analysis period.

Traditionally, clinicians preferred clinical laboratories for performing cardiac biomarkers tests for myocardial infarction, and to a limited extent, point-of-care. However, the POCT market for cardiac biomarkers showed dramatically upward trend with the introduction of the BNP test by Biosite in 2001. Clinical laboratory testing segment dominates the global cardiac biomarkers market, while Point-of-Care testing is poised to register the fastest CAGR of 12.9% during the analysis period.

Through the years, Siemens has transformed itself into the world’s largest fully integrated diagnostics company that includes laboratory diagnostics, imaging diagnostics, and clinical IT, all under one roof. Select major players profiled in the report include Abbott Diagnostics, Alere Inc., Axis-Shield PoC, Beckman Coulter Inc., BG Medicine, LifeSign LLC, Ortho-Clinical Diagnostics Inc., Roche Diagnostics Corp., among others.

The research report titled “Cardiac Biomarkers: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the Cardiac Biomarkers, its market overview, key market trends, trends in research and development, an overview of different tests available, applications in various therapeutic areas, recent industry activity, product launches, and profiles of select market participants. The report provides annual value sales estimates and projections for the Cardiac Biomarkers market for the years 2009 through 2017 for the US, Europe, and Rest of World markets.

For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Cardiac_Biomarkers_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website